Product Description:

Novel dual GIP/GLP-1, Tirzepatide, Tirzepatide CAS No. 2023788-19-2

Tirzepatide is a once-weekly dual agonist of the glucose-dependent insulinotropic polypeptide (GIP, also known as gastric inhibitory polypeptide) receptor and the glucagon-like peptide-1 (GLP-1) receptor, developed by Eli Lilly.

Both GIP and GLP-1 are hormones secreted by the intestines that can stimulate insulin secretion. Tirzepatide integrates the actions of these two insulinotropic hormones into a single molecule, representing a new class of drugs for the treatment of type 2 diabetes.